DOI:
10.1055/s-00000002
Aktuelle Dermatologie
LinksClose Window
References
Reich K, Armstrong AW, Foley P. et al.
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
J Am Acad Dermatol 2017;
76: 418-431
DOI: 10.1016/j.jaad.2016.11.042.
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.